Skip to content
Back to search

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Epinephrin (ATC-Code nach WHO: C01CA24) in der Darr. Fertigspritze/-pen

AOK PLUS - Die Gesundheitskasse für Sachsen und ThüringenGermanyPublished on Aug 02, 2026
378 days left

Description

The subject of this publication is the conclusion of non-exclusive discount agreements in accordance with § 130a para. 8 SGB V on medicinal products with the active substance Epinephrine (ATC code according to WHO: C01CA24) in the form of a pre-filled syringe/pre-filled pen - exclusive 500 micrograms. The contract is concluded within the framework of a so-called open-house model, i.e. a contract conclusion is open to all interested pharmaceutical companies within the participation period, provided they meet and accept the participation requirements. This means that individual contract negotiations are not conducted and (supply) exclusivity is not given. It is noted that the quantity to be procured is unknown, as it depends on demand and the development of the number of insured persons, on the prescribing behaviour of doctors and on the dispensing and stocking behaviour of public pharmacies. Accordingly, minimum procurement quantities are not guaranteed. Interested pharmaceutical entrepreneurs can download the participation documents via the project room of the German Tendering Portal (DTVP). To do this, an application for access to the project room is first required. After the applicant has been enabled by the contracting authority, the participation documents can be accessed. Absolute confidentiality must be maintained regarding the content of the participation documents - in particular regarding the content of the discount agreement and the discounts mentioned therein. Any full or partial disclosure or provision of contents of the participation documents to or for third parties requires the prior written consent of the contracting authority. If participation is waived, all documents must be destroyed immediately in accordance with data protection regulations. The documents to be submitted are listed in the documents "Cover Letter" and "Explanations of the Contract Terms" deposited in the project room. Communication, including the transmission of the participation documents, is carried out electronically via the tendering portal DTVP; details can be found in the aforementioned documents. Any contradictory information in the contract notice is due to technical reasons and is not binding. Participation applications can be submitted for the first time by 3 September 2026. All further submission deadlines can be found in the attachment "Submission Deadlines" deposited in the project room. If the deadline for submission falls on a Saturday, Sunday or a nationwide public holiday, the next working day shall take its place. In the event of late receipt, the submitted participation applications will be considered for the next submission deadline. The discount agreement ends, regardless of the date of conclusion of the contract, by 30 September 2027 at the latest. The contracting authority reserves the right to terminate the open-house procedure prematurely, in particular in the event of the conclusion of exclusive discount agreements; in this case, the discount agreements already concluded end in accordance with the contractual provisions. According to the experience of the contracting authority, exclusive discount agreements usually come into force 8 to 12 months after the publication of the corresponding contract notice in the Supplement to the Official Journal of the European Union.

CPV codes

Pharmaceutical products

Documents & submission

AI summary
Sign in for an AI summary

Contains data from Tenders Electronic Daily (TED), © European Union, ted.europa.eu — CC BY 4.0.

Related tenders